scholarly journals Influence of Referral Pathway on Ebola Virus Disease Case-Fatality Rate and Effect of Survival Selection Bias

2017 ◽  
Vol 23 (4) ◽  
pp. 597-600 ◽  
Author(s):  
Frauke Rudolf ◽  
Mads Damkjær ◽  
Suzanne Lunding ◽  
Kenn Dornonville de la Cour ◽  
Alyssa Young ◽  
...  
Keyword(s):  
Selection Bias ◽  
Case Fatality Rate ◽  
Ebola Virus ◽  
Virus Disease ◽  
Case Fatality ◽  
Ebola Virus Disease ◽  
Fatality Rate ◽  
Survival Selection ◽  
Disease Case

Ebola

2017 ◽  
Vol 10 (4) ◽  
pp. 228-232 ◽  
Author(s):  
Rabia Aftab
Keyword(s):  
Case Fatality Rate ◽  
Ebola Virus ◽  
Virus Disease ◽  
Case Fatality ◽  
Ebola Virus Disease ◽  
Contact Tracing ◽  
Fatality Rate ◽  
High Case Fatality Rate ◽  
Laboratory Service ◽  
Very High

Ebola virus disease is responsible for a very high case fatality rate of around 50–90%; it presents as a severe, rapidly developing illness. Several outbreaks of Ebola virus disease have occurred in Central and recently West Africa. Infection is transmitted to humans from animals and spreads within the human population through direct contact with infected blood or bodily fluids. No curative treatment is yet available, but early supportive care with rehydration and symptomatic management improves the chance of survival. Community engagement is needed to control outbreaks. Control of outbreaks requires a package of interventions including case management, surveillance and contact tracing with a good laboratory service, safe burials and social mobilisation. An Ebola vaccination may become available in the near future. The very high case fatality rate and recent major outbreaks require GPs to be aware of the presentation and management of suspected Ebola virus disease.

scholarly journals Case fatality rate for Ebola virus disease in west Africa

The Lancet ◽  
2014 ◽  
Vol 384 (9950) ◽  
pp. 1260 ◽  
Author(s):  
Adam J Kucharski ◽  
W John Edmunds
Keyword(s):  
West Africa ◽  
Case Fatality Rate ◽  
Ebola Virus ◽  
Virus Disease ◽  
Case Fatality ◽  
Ebola Virus Disease ◽  
Fatality Rate

JOINT ESTIMATION OF THE TRANSMISSIBILITY AND SEVERITY OF EBOLA VIRUS DISEASE IN REAL TIME

2017 ◽  
Vol 25 (04) ◽  
pp. 587-603 ◽  
Author(s):  
YUSUKE ASAI ◽  
HIROSHI NISHIURA
Keyword(s):  
Real Time ◽  
Ebola Virus ◽  
Virus Disease ◽  
Critical Role ◽  
Estimation Method ◽  
Case Fatality ◽  
Ascertainment Bias ◽  
Joint Estimation ◽  
Ebola Virus Disease ◽  
Strong Impact

The effective reproduction number [Formula: see text], the average number of secondary cases that are generated by a single primary case at calendar time [Formula: see text], plays a critical role in interpreting the temporal transmission dynamics of an infectious disease epidemic, while the case fatality risk (CFR) is an indispensable measure of the severity of disease. In many instances, [Formula: see text] is estimated using the reported number of cases (i.e., the incidence data), but such report often does not arrive on time, and moreover, the rate of diagnosis could change as a function of time, especially if we handle diseases that involve substantial number of asymptomatic and mild infections and large outbreaks that go beyond the local capacity of reporting. In addition, CFR is well known to be prone to ascertainment bias, often erroneously overestimated. In this paper, we propose a joint estimation method of [Formula: see text] and CFR of Ebola virus disease (EVD), analyzing the early epidemic data of EVD from March to October 2014 and addressing the ascertainment bias in real time. To assess the reliability of the proposed method, coverage probabilities were computed. When ascertainment effort plays a role in interpreting the epidemiological dynamics, it is useful to analyze not only reported (confirmed or suspected) cases, but also the temporal distribution of deceased individuals to avoid any strong impact of time dependent changes in diagnosis and reporting.

scholarly journals Use of Viremia to Evaluate the Baseline Case Fatality Ratio of Ebola Virus Disease and Inform Treatment Studies: A Retrospective Cohort Study

PLoS Medicine ◽  
2015 ◽  
Vol 12 (12) ◽  
pp. e1001908 ◽  
Author(s):  
Oumar Faye ◽  
Alessio Andronico ◽  
Ousmane Faye ◽  
Henrik Salje ◽  
Pierre-Yves Boëlle ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Ebola Virus ◽  
Virus Disease ◽  
Case Fatality ◽  
Ebola Virus Disease ◽  
Case Fatality Ratio ◽  
Baseline Case

scholarly journals Ebola virus disease: Case management in the Institute of Infectious Diseases, University Hospital of Sassari, Sardinia, Italy

2016 ◽  
Vol 10 (05) ◽  
pp. 537-543 ◽  
Author(s):  
Giulia Bertoli ◽  
Marco Mannazzu ◽  
Giordano Madeddu ◽  
Riccardo Are ◽  
Alberto Muredda ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Ebola Virus ◽  
Virus Disease ◽  
Developed Countries ◽  
The United States ◽  
Ebola Virus Disease ◽  
University Hospital ◽  
Governmental Organization ◽  
Medical Division ◽  
Disease Case

Since the onset of the worst epidemic of Ebola virus disease in December 2013, 28,637 cases were reported as confirmed, probable, or suspected. Since the week of 3 January 2016, no more cases have been reported. The total number of deaths have amounted to 11,315 (39.5%). In developed countries, seven cases have been diagnosed: four in the United States, one in Spain, one in the United Kingdom, and one in Italy. On 20 July 2015, Italy was declared Ebola-free. On 9 May 2015, an Italian health worker came back to Italy after a long stay in Sierra Leone working for a non-governmental organization. Forty-eight hours after his arrival, he noticed headache, weakness, muscle pains, and slight fever. The following day, he was safely transported to the Infectious Diseases Unit of University Hospital of Sassari. The patient was hospitalized for 19 hours until an Italian Air Force medical division transferred him to Rome, to the Lazzaro Spallanzani Institute. Nineteen people who had contacts with the patient were monitored daily for 21 days by the Public Health Office of Sassari and none presented any symptoms. So far, neither vaccine nor treatment is available to be proposed on an international scale. Ebola is considered a re-emerging infectious disease which, unlike in the past, has been a worldwide emergency. This case study aimed to establish a discussion about the operative and logistic difficulties to be faced and about the discrepancy arising when protocols clash with the reality of facts.

scholarly journals Effects of vaccines in protecting against Ebola virus disease: protocol for a systematic review

BMJ Open ◽  
2019 ◽  
Vol 9 (7) ◽  
pp. e029617 ◽  
Author(s):  
Lindi Mathebula ◽  
Duduzile Edith Ndwandwe ◽  
Elizabeth Pienaar ◽  
Charles Shey Wiysonge
Keyword(s):  
Systematic Review ◽  
Ebola Virus ◽  
Virus Disease ◽  
Data Extraction ◽  
Case Fatality ◽  
Fixed Effect Model ◽  
Ebola Virus Disease ◽  
Pool Data ◽  
Cochrane Central Register ◽  
Clinical Trial Registry

IntroductionEbola virus disease is one of the most devastating infectious diseases in the world with up to 90% case fatality observed. There are at least 13 candidate vaccines developed and being tested to prevent the occurrence of the Ebola virus disease. While none of these candidate vaccines has received regulatory approval for use, one candidate vaccine (rVSVΔG-ZEBOV-GP) has been granted access for emergency use. Two other candidate vaccines (GamEvac-Combi and Ad5-EBOV) have been licensed for emergency use in their countries of origin. The objective of this systematic review is to summarise the effects of the Ebola candidate vaccines in humans.Methods and analysisWe will search for potentially eligible studies, with no language or date restrictions, in the Cochrane Central Register of Controlled Trials, PubMed, Scopus, the WHO International Clinical Trial Registry Platform, and reference lists of relevant publications. The Cochrane Database of Systematic Reviews (CDSR) and the Database of Abstracts of Reviews of Effect (DARE) will be searched for related reviews. Two review authors will independently screen search records, assess study eligibility, perform data extraction, and assess the risk of bias; and reconcile their findings. We will pool data from similar studies using Mantel-Haenszel’s fixed-effect model.Ethics and disseminationThis study is exempted from ethical consideration since the data collected are publicly available and at no point will confidential information from human participants be used. We will disseminate our results through publications in peer-reviewed journals and relevant conferences.PROSPERO registration numberCRD42018110505.

The Epidemiological Presentation Pattern of Ebola Virus Disease Outbreaks: Changes from 1976 to 2019

2020 ◽  
Vol 35 (3) ◽  
pp. 247-253
Author(s):  
Pedro Arcos González ◽  
Ángel Fernández Camporro ◽  
Anneli Eriksson ◽  
Carmen Alonso Llada
Keyword(s):  
At Risk ◽  
Ebola Virus ◽  
Virus Disease ◽  
Disease Outbreaks ◽  
Case Fatality ◽  
Ebola Virus Disease ◽  
World Health ◽  
Study Objective ◽  
Population At Risk ◽  
Case Fatality Ratio

AbstractIntroduction:Ebola Virus Disease (EVD) is the international health emergency paradigm due to its epidemiological presentation pattern, impact on public health, resources necessary for its control, and need for a national and international response.Study Objective:The objective of this work is to study the evolution and progression of the epidemiological presentation profile of Ebola disease outbreaks since its discovery in 1976 to the present, and to explore the possible reasons for this evolution from different perspectives.Methods:Retrospective observational study of 38 outbreaks of Ebola disease occurred from 1976 through 2019, excluding laboratory accidents. United Nations agencies and programs; Ministries of Health; the US Centers for Disease Control and Prevention (CDC); ReliefWeb; emergency nongovernmental organizations; and publications indexed in PubMed, EmBase, and Clinical Key have been used as sources of data. Information on the year of the outbreak, date of beginning and end, duration of the outbreak in days, number of cases, number of deaths, population at risk, geographic extension affected in Km2, and time of notification of the first cases to the World Health Organization (WHO) have been searched and analyzed.Results:Populations at risk have increased (P = .024) and the geographical extent of Ebola outbreaks has grown (P = .004). Reporting time of the first cases of Ebola to WHO has been reduced (P = .017) and case fatality (P = .028) has gone from 88% to 62% in the period studied. There have been differences (P = .04) between the outbreaks produced by the Sudan and Zaire strains of the virus, both in terms of duration and case fatality ratio (Sudan strain 74.5 days on average and 62.7% of case fatality ratio versus Zaire strain with 150 days on average and 55.4% case fatality ratio).Conclusion:There has been a change in the epidemiological profile of the Ebola outbreaks from 1976 through 2019 with an increase in the geographical extent of the outbreaks and the population at risk, as well as a significant decrease in the outbreaks case fatality rate. There have been advances in the detection and management capacity of outbreaks, and the notification time to the WHO has been reduced. However, there are social, economic, cultural, and political obstacles that continue to greatly hinder a more efficient epidemiological approach to Ebola disease, mainly in Central Africa.

scholarly journals Ocular Manifestations of Ebola Virus Disease: An Ophthalmologist’s Guide to Prevent Infection and Panic

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Enzo Maria Vingolo ◽  
Giuseppe Alessio Messano ◽  
Serena Fragiotta ◽  
Leopoldo Spadea ◽  
Stefano Petti
Keyword(s):  
Ebola Virus ◽  
Virus Disease ◽  
Clinical Signs ◽  
Case Fatality ◽  
Hemorrhagic Fever ◽  
Ebola Virus Disease ◽  
Ocular Manifestations ◽  
Ebola Hemorrhagic Fever ◽  
Sub Saharan ◽  
The Moment

Ebola virus disease (EVD—formerly known as Ebola hemorrhagic fever) is a severe hemorrhagic fever caused by lipid-enveloped, nonsegmented, negative-stranded RNA viruses belonging to the genusEbolavirus. Case fatality rates may reach up to 76% of infected individuals, making this infection a deadly health problem in the sub-Saharan population. At the moment, there are still no indications on ophthalmological clinical signs and security suggestions for healthcare professionals (doctors and nurses or cooperative persons). This paper provides a short but complete guide to reduce infection risks.

scholarly journals “Association between air pollution in Lima and the high incidence of COVID-19: findings from a post hoc analysis.”

2021 ◽  
Author(s):  
Bertha V. Vasquez-Apestegui ◽  
Enrique Parras-Garrido ◽  
Vilma Tapia ◽  
Valeria M. Paz-Aparicio ◽  
Jhojan P. Rojas ◽  
...  
Keyword(s):  
Air Pollution ◽  
Case Fatality Rate ◽  
Virus Disease ◽  
Case Fatality ◽  
Fatality Rate ◽  
Food Markets ◽  
Early Implementation ◽  
High Incidence ◽  
Post Hoc

Abstract Background Corona virus disease (COVID-19) originated in China in December 2019. Thereafter, a global logarithmic expansion of the cases has occurred. Some countries have a higher rate of infections despite of early implementation of quarantine. Air pollution could be related to the high susceptibility to SARS-CoV-2 and the associated case-fatality rates (deaths/cases*100). Lima, Peru has the second highest incidence of COVID-19 in Latin America, and it is also one of the cities with highest levels of air pollution in the Region. Methods This study investigated the association of the levels of PM2.5 exposure in the previous years (2010–2016) in 24 districts of Lima with the positive-cases, deaths and case-fatality rates of COVID-19. Multiple Linear regression was used to evaluate this association controlled by age, sex, population density and number of food markets per district. The study period was from March 6 to June 12, 2020. Results There were in Lima 128,700 SARS-CoV-2 positive cases, and 2,382 deaths due to COVID-19. The case-fatality rate was 1.93%. Previous exposure to PM2.5 (years 2010—2016) was associated with number of Covid-19 positive-cases (β = 0.07; 95% CI: 0.034–0.107) and deaths (β = 0.0014; 95% CI: 0.0006–0.0.0023), but not with case-fatality rate. Conclusions the higher rates of COVID-19 in Metropolitan Lima is attributable, among others, to the increased PM2.5 exposure in the previous years after adjusting for age, sex and number of food markets. Reduction of air pollution since a long-term perspective, and social distancing are needed to prevent spreads of virus outbreak.

scholarly journals Emergence of Ebola Virus Disease (EVD): Key Facts

2015 ◽  
Vol 6 (1) ◽  
pp. 35-37
Author(s):  
Md Mahfuzar Rahman ◽  
Farnaz Mehrin ◽  
Fahim Ahmed
Keyword(s):  
Ebola Virus ◽  
Virus Disease ◽  
Virus Transmission ◽  
Specific Treatment ◽  
Case Fatality ◽  
Signs And Symptoms ◽  
Hemorrhagic Fever ◽  
Ebola Virus Disease ◽  
Background Information ◽  
Global Threat

The modern emerging infection Ebola Virus Disease (EVD) is of global threat originates from Africa region. This is zoonotic and identified as human diseases or previously called Ebola hemorrhagic fever which is a highly fatal human illness where case fatality rate is found up to 90%. The virus transmission begins from wild animals to human and then spreads within population through human to human. Fruit bats are found as natural host of Ebola virus. There is no specific treatment or vaccine available in the market so far, intensive supportive care is needed for severely ill patients. This paper highlights background information, problem statement, viral characteristics, mode of transmission, signs and symptoms, prevention & vaccination. It also indicates possible actions towards prevention of transmission & personal protection.Anwer Khan Modern Medical College Journal Vol. 6, No. 1: January 2015, Pages 35-37

Sign in / Sign up

Export Citation Format

Share Document